GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Concord Biotech Ltd

Concord Biotech Q2 FY27 Consolidated Revenue Rs. 30,907.02 lakhs, PAT Rs. 6,957.20 lakhs

RESULTS ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 27 Oct 2026, 07:03 PM IST  ·  BSE ID: 2135750b-1087-4f64-90ab-d78aa07be575
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported its latest quarterly financial results, announced a record date for bonus shares, and changed members of its internal committees.
🤖 AI Summary
  • Consolidated revenue from operations for Q2 FY27 stood at Rs. 30,907.02 lakhs.
  • Profit after tax for the second quarter ended September 30, 2026, was Rs. 6,957.20 lakhs.
  • The Board fixed Wednesday, November 04, 2026, as the record date for bonus equity shares.
  • Unaudited consolidated financial results for the half year ended September 30, 2026, were also approved.
  • Audit Committee, Nomination and Remuneration Committee, Risk Management Committee, and CSR Committee were reconstituted.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Consolidated Revenue from operations (Q2 FY27)
30,907.02 Rs. In lakhs
25.10
Consolidated Revenue from operations (Q2 FY26)
24,705.75 Rs. In lakhs
Consolidated Profit after tax (Q2 FY27)
6,957.20 Rs. In lakhs
10.32
Consolidated Profit after tax (Q2 FY26)
6,306.28 Rs. In lakhs
Consolidated Revenue from operations (H1 FY27)
56,655.92 Rs. In lakhs
25.61
Consolidated Revenue from operations (H1 FY26)
45,104.51 Rs. In lakhs
Consolidated Profit after tax (H1 FY27)
12,726.87 Rs. In lakhs
18.81
Consolidated Profit after tax (H1 FY26)
10,712.07 Rs. In lakhs
🏢 How This Affects the Company
📈
Business Impact
The company's consolidated revenue from operations for Q2 FY27 was Rs. 30,907.02 lakhs, indicating continued business activity. Consolidated revenue for H1 FY27 reached Rs. 56,655.92 lakhs.
💰
Financial Impact
Profit after tax on a consolidated basis for Q2 FY27 was Rs. 6,957.20 lakhs. For H1 FY27, consolidated profit after tax was Rs. 12,726.87 lakhs.
⚙️
Operational Impact
The reconstitution of key Board committees, including Audit and Risk Management, impacts internal governance and oversight structures. The record date for bonus shares requires administrative processing.
⚠️
Risk Impact
The limited review report notes that interim financial information of one subsidiary and one joint venture, which were not reviewed by the statutory auditor, reflect a total net loss after tax of Rs. (432.63) lakhs and Rs. (764.36) lakhs for the quarter and half-year respectively for the subsidiary, and a share of net profit of Rs. 29.06 lakhs and Rs. 35.32 lakhs for the quarter and half-year respectively for the joint venture.
👥 What This Means For Shareholders
✅
Action Required
Shareholders who wish to be eligible for the bonus equity shares must ensure they hold shares in their demat account on or before Wednesday, November 04, 2026, which is the record date.
👤
Who Is Affected
Shareholders holding Concord Biotech shares as of November 04, 2026, will be eligible to receive bonus equity shares. The proportion of bonus shares is not specified in this filing.
🔍
Management Signal
The decision to approve unaudited financial results, fix a record date for bonus shares, and reconstitute Board committees indicates ongoing corporate governance and capital allocation activities by management.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Bonus share allotment — confirm ratio and credit date.
Detailed investor presentation for Q2 FY27 — assess management commentary on performance.
Q3 FY27 financial results — check revenue and profit trends.
MEDIUM RISK Unaudited interim financial information for one subsidiary showing a net loss and unreviewed status noted by auditors.
💡 Investor Takeaway
Concord Biotech reported consolidated revenue from operations of Rs. 30,907.02 lakhs for Q2 FY27, an increase of 25.10% from Rs. 24,705.75 lakhs in Q2 FY26. Consolidated profit after tax grew by 10.32% to Rs. 6,957.20 lakhs in Q2 FY27 from Rs. 6,306.28 lakhs in Q2 FY26.
⚖️ Strengths & Concerns

✅ Positives

  • Consolidated revenue from operations increased to Rs. 30,907.02 lakhs in Q2 FY27 from Rs. 24,705.75 lakhs in Q2 FY26.
  • Consolidated profit after tax increased to Rs. 6,957.20 lakhs in Q2 FY27 from Rs. 6,306.28 lakhs in Q2 FY26.

⚠️ Concerns

  • The statutory auditor's limited review report mentions one subsidiary's unaudited interim financial information reflects a net loss after tax of Rs. (432.63) lakhs for Q2 FY27.
  • The statutory auditor's limited review report indicates this subsidiary's total comprehensive loss for Q2 FY27 was Rs. (450.82) lakhs from unaudited information.
📅 Company Track Record
In Q1 FY27, Concord Biotech reported a consolidated revenue increase of 26% to Rs. 257.5 Crs and PAT growth of 31%. This Q2 FY27 filing shows continued growth in revenue and PAT, extending the trend from the previous quarter.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Concord Biotech's consolidated revenue from operations for Q2 FY27?
Concord Biotech reported consolidated revenue from operations of Rs. 30,907.02 lakhs for the second quarter ended September 30, 2026.
What was the consolidated profit after tax for Concord Biotech in Q2 FY27?
The consolidated profit after tax for Concord Biotech for Q2 FY27 was Rs. 6,957.20 lakhs.
When is the record date for Concord Biotech's bonus equity shares?
The record date for the purpose of identifying shareholders eligible for bonus equity shares is Wednesday, November 04, 2026.
What were Concord Biotech's consolidated half-year results (H1 FY27) for revenue and profit?
For the half year ended September 30, 2026, Concord Biotech's consolidated revenue from operations was Rs. 56,655.92 lakhs and consolidated profit after tax was Rs. 12,726.87 lakhs.
Which committees of Concord Biotech's Board were reconstituted?
The Audit Committee, Nomination and Remuneration Committee, Risk Management Committee, and Corporate Social Responsibility Committee of Concord Biotech's Board were reconstituted.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.